1. Volume 3, Issue 2, Pages 117-127 (February 2016)
Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial 
Dr R Hamish McAllister-Williams, MD, Prof Ian M Anderson, MD, Andreas Finkelmeyer, PhD, Peter Gallagher, PhD, Prof Heinz C R Grunze, MD, Prof Peter M Haddad, MD, Tom Hughes, MD, Adrian J Lloyd, MD, Chrysovalanto Mamasoula, MSc, Prof Elaine McColl, PhD, Prof Simon Pearce, MD, Najma Siddiqi, PhD, Baxi N P Sinha, MD, Nick Steen, PhD, June Wainwright, PhD, Fiona H Winter, BSc, Prof I Nicol Ferrier, MD, Stuart Watson, MD 
The Lancet Psychiatry 
Volume 3, Issue 2, Pages (February 2016)
DOI: /S (15)
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet Psychiatry 2016 3, DOI: ( /S (15) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

3. Figure 2
Montgomery-Åsberg Depression Rating Scale (MADRS) scores of patients randomly assigned to metyrapone or placebo over time
Data are mean (datapoints) and SE (bars).
The Lancet Psychiatry 2016 3, DOI: ( /S (15) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

4. Figure 3
Baseline salivary cortisol concentrations of patients and matched healthy volunteers
Salivary cortisol concentrations at 2300 h and after awakening at baseline (week 0). The data after awakening was used to calculate the area under the curve (AUCG and AUCI) for the cortisol awakening response (CAR). Data are mean (datapoints) and SE (bars).
The Lancet Psychiatry 2016 3, DOI: ( /S (15) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

5. Figure 4 Patient retention in study over time
Kaplan-Meier curve for patients randomly assigned to metyrapone or placebo remaining in the study.
The Lancet Psychiatry 2016 3, DOI: ( /S (15) )
Copyright © 2016 Elsevier Ltd Terms and Conditions